Forte BioSciences Inc(FBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FBRX Forte BioSciences Inc

Market Closed 12-12 16:00:00 EST

21.37

-1.28

-5.65%

盘后21.37

+0.000.00%

19:44 EST

High23.71	Low21.36	Vol211.63K
Open22.68	D1 Closing22.65	Amplitude10.38%
Mkt Cap267.70M	Tradable Cap197.93M	Total Shares12.53M
T/O4.80M	T/O Rate2.28%	Tradable Shares9.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FBRX","market":"US","secType":"STK","nameCN":"Forte BioSciences Inc","latestPrice":21.37,"timestamp":1765573200000,"preClose":22.65,"halted":0,"volume":211626,"hourTrading":{"tag":"盘后","latestPrice":21.37,"preClose":21.37,"latestTime":"19:44 EST","volume":386,"amount":8277.02,"timestamp":1765586673632},"delay":0,"floatShares":9261900,"shares":12526935,"eps":-4.390928,"marketStatus":"Market Closed","change":-1.28,"latestTime":"12-12 16:00:00 EST","open":22.68,"high":23.71,"low":21.36,"amount":4795608.535272,"amplitude":0.103753,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.390928,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1492056000000,"exchange":"NASDAQ","adjPreClose":22.65,"preHourTrading":{"tag":"盘前","latestPrice":22.99,"preClose":22.65,"latestTime":"09:29 EST","volume":52,"amount":1194.9699839999998,"timestamp":1765549749465},"postHourTrading":{"tag":"盘后","latestPrice":21.37,"preClose":21.37,"latestTime":"19:44 EST","volume":386,"amount":8277.02,"timestamp":1765586673632},"volumeRatio":2.8288842210004512,"impliedVol":0.8843,"impliedVolPercentile":0.2772},"requestUrl":"/m/hq/s/FBRX","defaultTab":"news","newsList":[{"id":"2586473098","title":"Forte Biosciences Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473098","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586473098?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:07","pubTimestamp":1764076020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 08:07 ET (13:07 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX","BK4139"],"gpt_icon":0},{"id":"2586884490","title":"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2586884490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586884490?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:01","pubTimestamp":1764018060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUACN0YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2584255806","title":"Forte Biosciences Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584255806","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584255806?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:00 ET (13:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX","BK4139"],"gpt_icon":0},{"id":"2583686013","title":"Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583686013?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:30","pubTimestamp":1763148622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RenovoRx (RNXT – Research Report) and Forte Bioscien...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-renovorx-rnxt-and-forte-biosciences-fbrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-renovorx-rnxt-and-forte-biosciences-fbrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4585","BK4588","BK4539","HCSG","BK4139","BK4581","LU0128526141.USD","LU0029874061.USD","RNXT","XLV","XBI","LABU","FBRX"],"gpt_icon":0},{"id":"2583501214","title":"Forte Biosciences posts Q3 net loss of $17.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501214","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501214?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128842,"startTime":"0","endTime":"0","summary":"Forte Biosciences Inc. reported a net loss of $17.7 million for the third quarter of 2025, compared to a net loss of $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year period. Research and development expenses for the quarter were $15.1 million, up from $5.7 million a year earlier. General and administrative expenses were $3.2 million, compared to $2.8 million for the third quarter of 2024. As of September 30, 2025, Forte Biosciences had $93.4 million in cash and cash equivalents, with total assets at $97.1 million and stockholders' equity at $84.1 million. The company had approximately 12.5 million shares of common stock and 5.3 million prefunded warrants outstanding as of the end of the quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL5fk3qt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2583501191","title":"Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501191?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA1BXLSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBRX","BK4139"],"gpt_icon":0},{"id":"2583550123","title":"Forte Biosciences Q3 Basic EPS USD -0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2583550123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583550123?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX1D0ED4:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBRX","BK4139"],"gpt_icon":0},{"id":"2580240466","title":"Forte Biosciences to Present at Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580240466","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580240466?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:01","pubTimestamp":1762203684,"startTime":"0","endTime":"0","summary":"Forte Biosciences Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will present at the Guggenheim 2nd Annual Healthcare Innovation Conference at the InterContinental Boston on November 10 from 3:30 to 3:55 PM ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9C14sn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX","BK4139"],"gpt_icon":0},{"id":"2572663871","title":"BRIEF-Forte Biosciences Reports Inducement Grants Under Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2572663871","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572663871?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:03","pubTimestamp":1759521836,"startTime":"0","endTime":"0","summary":"BRIEF-Forte Biosciences Reports Inducement Grants Under Nasdaq Listing RulesOct 3 (Reuters) - Forte Biosciences Inc FBRX.O:FORTE BIOSCIENCES, INC. REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULESSource text: ID:nBw8DntXaFurther company coverage: FBRX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nTUAX6RL8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2572638788","title":"Forte Biosciences Announces Equity Inducement Awards for New Employees Under 2020 Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2572638788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572638788?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:01","pubTimestamp":1759521673,"startTime":"0","endTime":"0","summary":"Forte Biosciences Inc. has announced the grant of equity inducement awards to new non-executive employees. The awards consist of options to purchase a total of 125,000 shares of common stock. These stock options will vest over four years, with 25 percent vesting after the first year and the remaining 75 percent vesting in equal monthly installments over the following three years. The grants were made under Forte's 2020 Inducement Equity Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire  on October 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL6L63p8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX","BK4139"],"gpt_icon":0},{"id":"2567140941","title":"Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2567140941","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567140941?lang=en_us&edition=fundamental","pubTime":"2025-09-15 21:01","pubTimestamp":1757941273,"startTime":"0","endTime":"0","summary":"Forte Biosciences, Inc. , a clinical-stage biopharmaceutical company, has announced the presentation of results from its FB102 Celiac Disease Trial at the Tampere Celiac Disease Symposium in Finland. The oral presentation highlighted the outcomes of a phase 1b study which demonstrated that FB102 effectively prevents histological damage and mitigates gluten challenge-induced symptoms in patients with celiac disease. Key findings included a significant decline in TCR γδ density in patients treated with FB102 compared to those on placebo, as well as a reduction in Ki67-positive intraepithelial cell density and a 95% decline in NK cells. These results suggest that FB102 may offer a differentiated therapeutic option for celiac disease. The phase 2 trial is currently underway, with topline data anticipated in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL63rrPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2560579188","title":"Forte Biosciences Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2560579188","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560579188?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:13","pubTimestamp":1755522780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 09:13 ET (13:13 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2560907261","title":"Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2560907261","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560907261?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:31","pubTimestamp":1755520310,"startTime":"0","endTime":"0","summary":"Forte Biosciences (FBRX) has an average rating of Buy and mean price target of $52.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBRX"],"gpt_icon":0},{"id":"2559111759","title":"Forte Biosciences Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2559111759","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559111759?lang=en_us&edition=fundamental","pubTime":"2025-08-15 20:20","pubTimestamp":1755260400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 15, 2025 08:20 ET (12:20 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX"],"gpt_icon":0},{"id":"2559961066","title":"Forte Biosciences Q2 EPS $(0.96) Beats $(1.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559961066","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559961066?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:19","pubTimestamp":1755202774,"startTime":"0","endTime":"0","summary":"Forte Biosciences Q2 EPS $(0.96) Beats $(1.11) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47139022/forte-biosciences-q2-eps-0-96-beats-1-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Forte Biosciences Q2 EPS $(0.96) Beats $(1.11) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX"],"gpt_icon":0},{"id":"2559961680","title":"Forte Biosciences Inc. Reports Q2 2025 Net Loss of $11.25M, EPS at $(0.96), Continues Downward Trend from 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2559961680","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559961680?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:01","pubTimestamp":1755201706,"startTime":"0","endTime":"0","summary":"Forte Biosciences Inc. has released its second quarter 2025 financial results. The company reported a net loss of $11.249 million for the quarter, compared to a net loss of $12.511 million for the same period in 2024. The comprehensive loss for the quarter was $11.249 million, showing a slight improvement from the $12.516 million loss reported in the same period last year. The company's general and administrative expenses decreased to $2.96 million for the quarter, down from $7.078 million in the same period of 2024, primarily due to reduced professional and legal expenses. Conversely, research and development expenses increased to $8.6 million, compared to $5.7 million in the previous year, driven by a $3.8 million rise in clinical expenses. Forte ended the quarter with $106.1 million in cash and cash equivalents. The company also completed a public offering in June, selling 5,630,450 shares of common stock and pre-funded warrants, raising net proceeds of $69.9 million. In July, the u","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL9ZMhx7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX"],"gpt_icon":0},{"id":"2559961530","title":"Forte Biosciences, Inc. Announces Results and Provides Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559961530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559961530?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:01","pubTimestamp":1755201660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA7CJT7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2559507961","title":"Forte Biosciences Inc - Expects Three FB102 Trial Readouts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2559507961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559507961?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:01","pubTimestamp":1755201660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA7CJT7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2559796159","title":"Forte Biosciences Q2 Basic EPS USD -0.96","url":"https://stock-news.laohu8.com/highlight/detail?id=2559796159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559796159?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:01","pubTimestamp":1755201660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX4829CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBRX"],"gpt_icon":0},{"id":"2557218465","title":"Forte Biosciences Inc  expected to post a loss of $1.11 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557218465","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557218465?lang=en_us&edition=fundamental","pubTime":"2025-08-08 19:57","pubTimestamp":1754654239,"startTime":"0","endTime":"0","summary":"Forte Biosciences Inc  expected to post a loss of $1.11 a share - Earnings Preview Forte Biosciences Inc FBRX.OQ FBRX.O is expected to  show no change in quarterly revenue when it reports  results on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U01TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fortebiorx.com","stockEarnings":[{"period":"1week","weight":0.0723},{"period":"1month","weight":0.4779},{"period":"3month","weight":1.0237},{"period":"6month","weight":0.7683},{"period":"1year","weight":-0.0721},{"period":"ytd","weight":-0.059}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.032572},{"month":2,"riseRate":0.375,"avgChangeRate":0.11866},{"month":3,"riseRate":0.5,"avgChangeRate":0.020739},{"month":4,"riseRate":0.375,"avgChangeRate":-0.055367},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.027133},{"month":6,"riseRate":0.333333,"avgChangeRate":0.026635},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.045355},{"month":8,"riseRate":0.555556,"avgChangeRate":0.015227},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.106302},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.15298},{"month":11,"riseRate":0.555556,"avgChangeRate":0.494702},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009569}],"exchange":"NASDAQ","name":"Forte BioSciences Inc","nameEN":"Forte BioSciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Forte BioSciences Inc(FBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Forte BioSciences Inc(FBRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Forte BioSciences Inc,FBRX,Forte BioSciences Inc股票,Forte BioSciences Inc股票老虎,Forte BioSciences Inc股票老虎国际,Forte BioSciences Inc行情,Forte BioSciences Inc股票行情,Forte BioSciences Inc股价,Forte BioSciences Inc股市,Forte BioSciences Inc股票价格,Forte BioSciences Inc股票交易,Forte BioSciences Inc股票购买,Forte BioSciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Forte BioSciences Inc(FBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Forte BioSciences Inc(FBRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}